K2 Principal Fund’s AbbVie ABBV Stock Holding History

K2 Principal Fund’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-20,000	Closed	-$2.16M	–	365
2021 Q1	$2.16M	Sell	20,000 -5,000	-20%	-$535K	0.17%	152
2020 Q4	$2.68M	Hold	25,000	–	–	0.23%	115
2020 Q3	$2.19M	Buy	+25,000	New	+$2.35M	0.33%	106
2015 Q3	–	Sell	-9,000	Closed	-$605K	–	156
2015 Q2	$605K	Buy	+9,000	New	+$588K	0.11%	120
2015 Q1	–	Sell	-21,000	Closed	-$1.37M	–	154
2014 Q4	$1.37M	Buy	+21,000	New	+$1.32M	0.32%	69

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return

K2 Principal Fund's ABBV Position: Q3 2015 in Review

K2 Principal Fund sold out of AbbVie (ABBV) in Q3 2015, closing a stake of 14,022 shares — an estimated $942K sold.

K2 Principal Fund first reported a position in ABBV in Q4 2014 and held it in 2 quarters. The position peaked at $942K in Q2 2015. 1,604 funds tracked by Wall St. Rank hold ABBV as of Q3 2015.

K2 Principal Fund reported no remaining AbbVie position as of Q3 2015 after selling out during the quarter.
K2 Principal Fund sold 14,022 AbbVie shares in Q3 2015, an estimated $942K.
K2 Principal Fund first reported a position in AbbVie in Q4 2014 and held it in 2 quarters.
K2 Principal Fund's AbbVie position peaked at $942K in Q2 2015.
1,604 funds tracked by Wall St. Rank held AbbVie as of Q3 2015.

Based on K2 Principal Fund's 13F filing for Q3 2015, filed 13 Nov 2015.